Business Context and Reporting Period
This Form 8-K was filed by Intensity Therapeutics, Inc. on December 11, 2023. The report discloses the appointment of a new Chief Financial Officer and the departure of the interim CFO. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding executive compensation and personnel changes. It does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial statements are included in this document.
Material Changes
The primary material change reported is the leadership transition within the finance function:
- Appointment: Joseph Talamo was appointed Chief Financial Officer (CFO) effective December 11, 2023.
- Departure: John Wesolowski, who served as Interim CFO since June 2023, will no longer serve in that capacity but will remain as Principal Accounting Officer and Controller.
Management Commentary, Risks, and Unusual Items
Compensation and Employment Terms for Joseph Talamo:
- Base Salary: $370,000 per year.
- Target Bonus: Up to 35% of Base Salary based on performance.
- Equity Grant: 80,000 stock options with an exercise price of $6.88, vesting in four equal annual installments.
- Severance:
- Termination without Cause or resignation for Good Reason: 1 month of Base Salary for the first year, increasing by 1 month per anniversary year, up to a maximum of 6 months.
- Change in Control: 4 to 6 months of Base Salary depending on tenure (1 to 3 years).
- Restrictions: Includes a 12-month non-compete and non-solicitation period post-employment.
Risks and Contingencies: The filing notes that post-employment benefits are contingent upon the execution of a general release of claims. No other specific risks or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for detailed definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the vesting schedule and exercise price of the 80,000 stock options granted to Mr. Talamo.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the leadership change.
- Check subsequent filings (e.g., 10-K or 10-Q) for the company's actual financial performance, as this 8-K contains no financial data.